Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100)

David Cella; Molin Wang; Lynne Wagner; Kathy Miller

doi:10.1007/s10549-011-1725-6

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100)

David Cella, Molin Wang, Lynne Wagner^*, Kathy Miller

^*Corresponding author for this work

Medical Social Sciences

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

The purpose of this study was to examine health-related quality of life (HRQL) among women with metastatic breast cancer treated on E2100 with paclitaxel or paclitaxel plus bevacizumab. Trial participants (N = 670) completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) pre-treatment and following 4 and 8 cycles of treatment to assess HRQL and breast cancer-specific concerns. A significantly higher proportion of missing FACT-B assessments was observed among patients receiving paclitaxel only, due to faster time to death. To account for this non-ignorable pattern of missing data, we conducted a survival-adjusted HRQL analysis by jointly modeling the longitudinal HRQL outcome and time to non-ignorable dropout using a two-stage model. FACT scores assessing HRQL did not differ following 4 and 8 cycles of treatment; however mean scores on the 9-item Breast Cancer Scale were significantly higher after 4 and 8 cycles of treatment among patients receiving paclitaxel plus bevacizumab. No differences were observed between treatment arms on FACT-B total scores. The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted.

Original language	English (US)
Pages (from-to)	855-861
Number of pages	7
Journal	Breast Cancer Research and Treatment
Volume	130
Issue number	3
DOIs	https://doi.org/10.1007/s10549-011-1725-6
State	Published - Dec 2011

Funding

Acknowledgments This study was supported in part by Public Health Service Grants (Grant numbers CA23318, CA66636, CA21115, CA49883, and CA16116) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, and by Genentech, Inc. David Cella, Ph.D. consulting honoraria received research funding from Genentech, Inc. Kathy Miller, M.D. consulting honoraria and speaker’s bureau from Genentech, Inc. No other authors have disclosures to report.

Keywords

Health-related quality of life
Metastatic breast cancer
Patient-reported outcomes
Survival-adjusted quality of life

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-011-1725-6

Fingerprint

Dive into the research topics of 'Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100)'. Together they form a unique fingerprint.

Cite this

Cella, D., Wang, M., Wagner, L., & Miller, K. (2011). Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Research and Treatment, 130(3), 855-861. https://doi.org/10.1007/s10549-011-1725-6

@article{e3d925d9ec964a0b84ebd84a808c704d,

title = "Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100)",

abstract = "The purpose of this study was to examine health-related quality of life (HRQL) among women with metastatic breast cancer treated on E2100 with paclitaxel or paclitaxel plus bevacizumab. Trial participants (N = 670) completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) pre-treatment and following 4 and 8 cycles of treatment to assess HRQL and breast cancer-specific concerns. A significantly higher proportion of missing FACT-B assessments was observed among patients receiving paclitaxel only, due to faster time to death. To account for this non-ignorable pattern of missing data, we conducted a survival-adjusted HRQL analysis by jointly modeling the longitudinal HRQL outcome and time to non-ignorable dropout using a two-stage model. FACT scores assessing HRQL did not differ following 4 and 8 cycles of treatment; however mean scores on the 9-item Breast Cancer Scale were significantly higher after 4 and 8 cycles of treatment among patients receiving paclitaxel plus bevacizumab. No differences were observed between treatment arms on FACT-B total scores. The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted.",

keywords = "Health-related quality of life, Metastatic breast cancer, Patient-reported outcomes, Survival-adjusted quality of life",

author = "David Cella and Molin Wang and Lynne Wagner and Kathy Miller",

note = "Funding Information: Acknowledgments This study was supported in part by Public Health Service Grants (Grant numbers CA23318, CA66636, CA21115, CA49883, and CA16116) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, and by Genentech, Inc. David Cella, Ph.D. consulting honoraria received research funding from Genentech, Inc. Kathy Miller, M.D. consulting honoraria and speaker{\textquoteright}s bureau from Genentech, Inc. No other authors have disclosures to report.",

year = "2011",

month = dec,

doi = "10.1007/s10549-011-1725-6",

language = "English (US)",

volume = "130",

pages = "855--861",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "3",

}

Cella, D, Wang, M, Wagner, L & Miller, K 2011, 'Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100)', Breast Cancer Research and Treatment, vol. 130, no. 3, pp. 855-861. https://doi.org/10.1007/s10549-011-1725-6

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100). / Cella, David; Wang, Molin; Wagner, Lynne et al.
In: Breast Cancer Research and Treatment, Vol. 130, No. 3, 12.2011, p. 855-861.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone

T2 - Results from Eastern Cooperative Oncology Group Study 2100 (E2100)

AU - Cella, David

AU - Wang, Molin

AU - Wagner, Lynne

AU - Miller, Kathy

N1 - Funding Information: Acknowledgments This study was supported in part by Public Health Service Grants (Grant numbers CA23318, CA66636, CA21115, CA49883, and CA16116) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, and by Genentech, Inc. David Cella, Ph.D. consulting honoraria received research funding from Genentech, Inc. Kathy Miller, M.D. consulting honoraria and speaker’s bureau from Genentech, Inc. No other authors have disclosures to report.

PY - 2011/12

Y1 - 2011/12

N2 - The purpose of this study was to examine health-related quality of life (HRQL) among women with metastatic breast cancer treated on E2100 with paclitaxel or paclitaxel plus bevacizumab. Trial participants (N = 670) completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) pre-treatment and following 4 and 8 cycles of treatment to assess HRQL and breast cancer-specific concerns. A significantly higher proportion of missing FACT-B assessments was observed among patients receiving paclitaxel only, due to faster time to death. To account for this non-ignorable pattern of missing data, we conducted a survival-adjusted HRQL analysis by jointly modeling the longitudinal HRQL outcome and time to non-ignorable dropout using a two-stage model. FACT scores assessing HRQL did not differ following 4 and 8 cycles of treatment; however mean scores on the 9-item Breast Cancer Scale were significantly higher after 4 and 8 cycles of treatment among patients receiving paclitaxel plus bevacizumab. No differences were observed between treatment arms on FACT-B total scores. The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted.

AB - The purpose of this study was to examine health-related quality of life (HRQL) among women with metastatic breast cancer treated on E2100 with paclitaxel or paclitaxel plus bevacizumab. Trial participants (N = 670) completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) pre-treatment and following 4 and 8 cycles of treatment to assess HRQL and breast cancer-specific concerns. A significantly higher proportion of missing FACT-B assessments was observed among patients receiving paclitaxel only, due to faster time to death. To account for this non-ignorable pattern of missing data, we conducted a survival-adjusted HRQL analysis by jointly modeling the longitudinal HRQL outcome and time to non-ignorable dropout using a two-stage model. FACT scores assessing HRQL did not differ following 4 and 8 cycles of treatment; however mean scores on the 9-item Breast Cancer Scale were significantly higher after 4 and 8 cycles of treatment among patients receiving paclitaxel plus bevacizumab. No differences were observed between treatment arms on FACT-B total scores. The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted.

KW - Health-related quality of life

KW - Metastatic breast cancer

KW - Patient-reported outcomes

KW - Survival-adjusted quality of life

UR - http://www.scopus.com/inward/record.url?scp=82255174987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82255174987&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1725-6

DO - 10.1007/s10549-011-1725-6

M3 - Article

C2 - 21874312

AN - SCOPUS:82255174987

SN - 0167-6806

VL - 130

SP - 855

EP - 861

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 3

ER -

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100)

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this